TrialBMC women's health2021

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.

Yutaka Osuga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.